Compare Enovix Corporation (ENVX) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Koninklijke Philips NV — how do they compare? Enovix Corporation trades at $4.88 (market cap $1.11B), while Koninklijke Philips NV trades at $27.07 (market cap $26.29B). The key difference: Koninklijke Philips NV is far larger — about 23.7× Enovix Corporation's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | PHG | |
|---|---|---|
Market Cap | $1.11B | $26.29B |
Sector | Technology | Health |
52-Week High | $15.93 | $32.91 |
52-Week Low | $4.84 | $24.38 |
Enterprise Value | $1.13B | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
Royal Philips (PHG) trades at $26.06, down 4.68% today, with bearish technical signals but improving fundamentals. The company reported strong Q1 2026 earnings beat and maintains a 5.5% net income margin. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight innovation momentum. Cash flow remains positive at $403M for 2025, though debt-to-asset ratio increased to 25.44%.
PHG shows recovery potential with earnings growth and AI healthcare adoption, but faces execution risks and technical weakness. Analyst consensus leans Hold (59%) with no Sell ratings, suggesting cautious optimism. Key risks include competitive pressures and macroeconomic volatility affecting medical equipment demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
